Table III.
Demographics by analysis population and treatment areas
| All DBPC |
GL DBPC |
CFL DBPC |
CFL + GL DBPC |
FHL + GL DBPC |
FHL + GL + CFL DBPC |
All OnabotA |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OnabotA (N = 3431) | Placebo (N = 1359) | OnabotA (N = 665) | Placebo (N = 236) | OnabotA (N = 1324) | Placebo (N = 808) | OnabotA (N = 405) | Placebo (N = 306) | OnabotA (N = 724) | Placebo (N = 315) | OnabotA (N = 313) | Placebo (N = 156) | (N = 4449) | |
| Age, y | |||||||||||||
| Median | 47.0 | 47.0 | 44.0 | 46.0 | 48.0 | 47.0 | 50.0 | 49.0 | 47.0 | 47.0 | 45.0 | 48.0 | 47.0 |
| Range | 18-85 | 22-74 | 22-78 | 22-69 | 22-75 | 22-74 | 24-85 | 25-73 | 18-77 | 22-73 | 21-76 | 22-73 | 18-85 |
| Sex, n (%) | |||||||||||||
| Female | 2953 (86.1) | 1163 (85.6) | 557 (83.8) | 203 (86.0) | 1131 (85.4) | 681 (84.3) | 355 (87.7) | 263 (85.9) | 626 (86.5) | 279 (88.6) | 284 (90.7) | 140 (89.7) | 3860 (86.8) |
| Male | 478 (13.9) | 196 (14.4) | 108 (16.2) | 33 (14.0) | 193 (14.6) | 127 (15.7) | 50 (12.3) | 43 (14.1) | 98 (13.5) | 36 (11.4) | 29 (9.3) | 16 (10.3) | 589 (13.2) |
| Race, n (%) | |||||||||||||
| White | 2379 (69.3) | 933 (68.7) | 341 (51.3) | 107 (45.3) | 740 (55.9) | 543 (67.2) | 358 (88.4) | 265 (86.6) | 655 (90.5) | 283 (89.8) | 285 (91.1) | 145 (92.9) | 2657 (59.7) |
| Asian | 822 (24.0) | 329 (24.2) | 269 (40.5) | 110 (46.6) | 529 (40.0) | 209 (25.9) | 6 (1.5) | 6 (2.0) | 16 (2.2) | 10 (3.2) | 2 (0.6) | 1 (0.6) | 1530 (34.4) |
| Black | 48 (1.4) | 24 (1.8) | 21 (3.2) | 7 (3.0) | 12 (0.9) | 10 (1.2) | 4 (1.0) | 2 (0.7) | 9 (1.2) | 7 (2.2) | 2 (0.6) | 3 (1.9) | 57 (1.3) |
| Other | 182 (5.3) | 73 (5.4) | 34 (5.1) | 12 (5.1) | 43 (3.2) | 46 (5.7) | 37 (9.1) | 33 (10.8) | 44 (6.1) | 15 (4.8) | 24 (7.7) | 7 (4.5) | 205 (4.6) |
CFL, Crow’s feet lines; DBPC, double-blind placebo-controlled; FHL, forehead lines; GL, glabellar lines; OnabotA, onabotulinumtoxinA.